Priya Singhal
Corporate Officer/Principal bij BIOGEN INC.
Vermogen: 1 M $ op 31-05-2024
Actieve functies van Priya Singhal
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 02-10-2023 | - |
| Hoofd Techniek/Wetenschap/O&O | 31-12-2021 | 02-10-2023 |
Loopbaan van Priya Singhal
Eerdere bekende functies van Priya Singhal
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Hoofd Techniek/Wetenschap/O&O | 01-01-2008 | 01-01-2012 |
| LARIMAR THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 04-03-2019 | - |
Opleiding van Priya Singhal
| Harvard T.H. Chan School of Public Health | Graduate Degree |
| University of Mumbai | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| India | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Priya Singhal
- Ervaring
